Clinical Trials Browser

Decitabine × Gastrointestinal × Clear all

NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT05360264 2025-03-24

ORIENTATE

Phase 2 Terminated

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1/2 Terminated

9 enrolled 14 charts

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT01882660 2022-12-19

DECO

Phase NA Terminated

Gastrointestinal

Colonic Neoplasms

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Phase EARLY_PHASE1 Completed

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02685228 2016-02-18

SLOWDOSE001

Phase NA Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT00019825 2015-04-29

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Phase 1 Completed

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant, Small Cell Lung Carcinoma